Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
COLESEVELAM HYDROCHLORIDE vs ADDERALL 30
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Colesevelam hydrochloride is a bile acid sequestrant that binds bile acids in the intestine, forming an insoluble complex excreted in feces. This reduces enterohepatic circulation of bile acids, leading to increased conversion of cholesterol to bile acids in the liver and upregulation of LDL receptors, resulting in decreased serum LDL cholesterol. In diabetes, it improves glycemic control possibly by altering bile acid signaling via FXR and TGR5 receptors, affecting hepatic glucose production and incretin release.
Adderall contains mixed amphetamine salts that increase synaptic levels of dopamine and norepinephrine by inhibiting their reuptake and promoting release from presynaptic terminals.
Adjunctive therapy to diet and exercise for reduction of elevated LDL cholesterol in adults with primary hyperlipidemia,Monotherapy or combination therapy for homozygous familial hypercholesterolemia,Adjunctive therapy to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus,Off-label: Pediatric primary hyperlipidemia
Attention Deficit Hyperactivity Disorder (ADHD),Narcolepsy
3.75 g orally once daily or divided as 1.875 g twice daily with meals and liquid; maximum 4.375 g/day.
Initial: 5 mg orally once or twice daily; increase by 5 mg increments weekly; usual maintenance: 20-30 mg daily in divided doses; maximum: 40 mg/day
Not applicable as colesevelam is not absorbed; it acts locally in the gastrointestinal tract.
Terminal elimination half-life: d-amphetamine 10-13 hours, l-amphetamine 13-15 hours; in adults (children: 6-8 hours). The longer half-life allows for once-daily dosing.
Colesevelam is not systemically absorbed (<0.05%) and undergoes negligible metabolism.
Primarily hepatic via CYP2D6, with minor contributions from CYP1A2, CYP2B6, and CYP3A4.
Colesevelam is not absorbed systemically; it is excreted unchanged in the feces via biliary elimination. No renal excretion occurs.
Approximately 30-40% of a dose is excreted unchanged in urine; the remainder is metabolized primarily by oxidative deamination and aromatic hydroxylation. Biliary/fecal elimination accounts for less than 5%.
0% (not absorbed; no systemic protein binding).
Approximately 20-25% bound to plasma proteins, mainly albumin and alpha-1-acid glycoprotein.
Not applicable; drug is not systemically absorbed and remains confined to the gastrointestinal lumen.
Vd: 3-4 L/kg (approximately 210-280 L for a 70 kg adult). This indicates extensive tissue distribution and penetration into the central nervous system.
<0.1% after oral administration; essentially not absorbed.
Oral immediate-release: approximately 75-100%; oral extended-release: approximately 94% relative to immediate-release. Food does not significantly affect absorption but may delay peak concentration.
No dose adjustment required for renal impairment; not systemically absorbed.
GFR 30-89 m L/min: no adjustment; GFR 15-29 m L/min: reduce dose by 50%; GFR <15 m L/min: avoid use
No dose adjustment required for hepatic impairment.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use
Not approved for pediatric patients; safety and efficacy not established.
Children 3-5 years: initial 2.5 mg orally once daily; increase by 2.5 mg weekly; usual range 2.5-20 mg/day. Children ≥6 years: initial 5 mg once or twice daily; increase by 5 mg weekly; usual range 5-40 mg/day in divided doses
No specific dose adjustment; use with caution due to potential for constipation and gastrointestinal obstruction.
Initiate at 2.5 mg orally once or twice daily; titrate slowly; monitor for cardiovascular effects, insomnia, and weight loss
No FDA black box warning.
Amphetamines have a high potential for abuse and dependence. Misuse may cause sudden death or serious cardiovascular events.
May cause hypertriglyceridemia (monitor triglycerides),Risk of fat-soluble vitamin deficiency (Vitamins A, D, E, K) with prolonged use,May reduce absorption of: oral contraceptives, cyclosporine, warfarin, thyroid hormone, and other drugs (administer 4 hours before or after Colesevelam),Patients with hemorrhoids or history of severe GI obstruction risk,May cause constipation, dyspepsia, and abdominal pain
Risk of serious cardiovascular events including sudden death in patients with pre-existing structural cardiac abnormalities,Increased blood pressure and heart rate,Psychiatric adverse events including exacerbation of pre-existing psychosis, mania, or aggressive behavior,Serotonin syndrome risk when co-administered with serotonergic drugs,Long-term suppression of growth in children,Seizure risk in patients with history of seizures,Peripheral vasculopathy including Raynaud's phenomenon,Visual disturbances due to mydriasis
Bowel obstruction or history of bowel obstruction,Hypertriglyceridemia-induced pancreatitis,Elevated serum triglycerides >500 mg/d L,Hypersensitivity to colesevelam or any component
Advanced arteriosclerosis,Symptomatic cardiovascular disease,Moderate to severe hypertension,Hyperthyroidism,Known hypersensitivity to amphetamines,Agitated states,History of drug abuse,During or within 14 days of MAO inhibitor use,Glaucoma
Take with meals to enhance bile acid binding. Avoid high-fat meals that may reduce efficacy. Colesevelam may interfere with absorption of fat-soluble vitamins (A, D, E, K); consider supplementation if long-term use. Grapefruit juice has no documented interaction.
Avoid high-fat meals as they delay absorption; avoid acidic foods (e.g., citrus) and vitamin C supplements within 1 hour of dosing as they decrease absorption; limit caffeine and other stimulants to avoid additive cardiovascular effects.
Colesevelam hydrochloride is not systemically absorbed (<0.05% oral bioavailability). No fetal risk is expected. No adequate and well-controlled studies in pregnant women. Based on animal studies, no evidence of harm at doses up to 1.5 times human dose. Insufficient data for first trimester; however, given negligible absorption, teratogenic risk is considered negligible across all trimesters.
Pregnancy category C. First trimester: No well-controlled studies, but potential for congenital malformations not definitively established. Second and third trimesters: Increased risk of premature delivery, low birth weight, and neonatal withdrawal symptoms (e.g., dysphoria, agitation, lassitude). Chronic use may lead to neonatal toxicity.
Colesevelam is not absorbed systemically; therefore, excretion into breast milk is negligible. M/P ratio: not applicable. Considered compatible with breastfeeding by most sources.
Excreted in breast milk. M/P ratio unknown. Potential for stimulant effects in infant (e.g., irritability, poor feeding, insomnia). Caution advised; consider alternative feeding methods.
No dosing adjustment is necessary. Colesevelam's pharmacokinetics are unaffected by pregnancy due to negligible systemic absorption. Dose should be based on clinical response to hyperlipidemia. Standard adult dosing: 3 tablets (625 mg each) twice daily or 6 tablets once daily with food and liquid.
No established dosing guidelines. Due to increased plasma volume and clearance, dose may need titration to clinical effect, but avoid supratherapeutic doses. Use lowest effective dose.
Colesevelam is a bile acid sequestrant that reduces LDL-C and improves glycemic control in type 2 diabetes. Administer with meals to maximize bile acid binding. Monitor triglycerides as levels may increase. Separate dosing from other medications (e.g., levothyroxine, warfarin) by at least 4 hours to avoid reduced absorption. Can be mixed with water, fruit juice, or soft foods.
For ADHD: start low, go slow; monitor weight and height in children; avoid late doses to prevent insomnia; check for abuse/diversion; screen for bipolar disorder and hypertension; consider urine drug screen before prescribing; avoid MAOIs within 14 days; use with caution in seizure disorders and glaucoma.
Take this medication with a meal and at least 4 hours after any other medications.,Mix powder with 4-8 ounces of water, fruit juice, or soft food (e.g., applesauce) and consume within 24 hours.,Do not take without food; it may cause stomach upset.,Common side effects include constipation, gas, and indigestion; drink plenty of fluids and increase fiber intake.,This medication can increase triglyceride levels; your doctor will monitor your blood.,Inform your doctor if you have a history of pancreatitis or gallbladder disease.,Keep out of reach of children and store at room temperature.
Take exactly as prescribed; do not crush or chew capsules.,Take the first dose upon waking; avoid afternoon/evening doses.,May cause insomnia, loss of appetite, or nervousness.,Do not drink alcohol while taking this medication.,Report chest pain, palpitations, shortness of breath, or mood changes.,Store securely; do not share medication with others.,Regular blood pressure and heart rate monitoring is necessary.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about COLESEVELAM HYDROCHLORIDE vs ADDERALL 30, answered by our medical review team.
COLESEVELAM HYDROCHLORIDE is a Bile Acid Sequestrant that works by Colesevelam hydrochloride is a bile acid sequestrant that binds bile acids in the intestine, forming an insoluble complex excreted in feces. This reduces enterohepatic circulation of bile acids, leading to increased conversion of cholesterol to bile acids in the liver and upregulation of LDL receptors, resulting in decreased serum LDL cholesterol. In diabetes, it improves glycemic control possibly by altering bile acid signaling via FXR and TGR5 receptors, affecting hepatic glucose production and incretin release.. ADDERALL 30 is a CNS Stimulant that works by Adderall contains mixed amphetamine salts that increase synaptic levels of dopamine and norepinephrine by inhibiting their reuptake and promoting release from presynaptic terminals.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between COLESEVELAM HYDROCHLORIDE and ADDERALL 30 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of COLESEVELAM HYDROCHLORIDE is: 3.75 g orally once daily or divided as 1.875 g twice daily with meals and liquid; maximum 4.375 g/day.. The standard adult dose of ADDERALL 30 is: Initial: 5 mg orally once or twice daily; increase by 5 mg increments weekly; usual maintenance: 20-30 mg daily in divided doses; maximum: 40 mg/day. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between COLESEVELAM HYDROCHLORIDE and ADDERALL 30 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. COLESEVELAM HYDROCHLORIDE is classified as Category A/B. Colesevelam hydrochloride is not systemically absorbed (<0.05% oral bioavailability). No fetal risk is expected. No adequate and well-controlled studies in pregnant women. Based on. ADDERALL 30 is classified as Category C. Pregnancy category C. First trimester: No well-controlled studies, but potential for congenital malformations not definitively established. Second and third trimesters: Increased r. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.